The cycles of DEB-BACE/BAI [hazard ratio (HR): 0.363, 95% CI: 0.202–0.655, P = 0.001; Figure 4A] and postoperative immunotherapy (HR: 0.219, 95% CI: 0.085–0.561, P = 0.002; Figure 4B) were identified as the predictors of OS for ASTRI-NSCLC treated with DEB-BACE. The gene discussed is BACE1; the disease is non-small cell lung carcinoma.